“NILS BRÜNNER, FORMER FRONTMAN OF SCANDION ONCOLOGY, RETURNS TO THE MANAGEMENT OF A BIOTECH COMPANY.”
For the last 9 months,
Metsystem has enjoyed the sage advice of our trusted medical advisor,
Nils Brünner.
Today, we officially welcome him onboard as Chief Medical Officer!
We are grateful for such a valuable addition to our team!
Nils Brünner, MD, DMSc is a key opinion leader in the field of drug resistance in cancer. He has authored more than 370 scientific papers, mostly focusing on translational cancer research. He has developed many of the drug-resistant cancer cell lines that are used in drug developmental research today. Dr. Brünner has deep experience translating research breakthroughs into the clinic.
He trained in internal medicine and medical oncology in Copenhagen and in molecular and cellular biology at the
National Cancer Institute (NCI) in Bethesda, MD, USA and
Lombardi Cancer Ctr, Washington DC, USA. In 2002, he became a full Professor at University of Copenhagen’s Faculty of Health and Medical Sciences. He is now Professor Emeritus. Dr. Brunner co-founded
Scandion Oncology and Oncology Ventures A/S; he served on the Board of Directors of
WntResearch AB,
2cureX – Individualizing Cancer Treatment, and
Scandion Oncology; and he’s currently CEO of 3B-Oncology. Today, we are delighted to announce him as CMO of
Metsystem.
Welcome, Nils!
Optimum Perspectives Podcast featuring Metsystem CEO Ninna Struck Rossen
International Day of Women & Girls in Science: Breaking barriers and channeling your inner cavewoman
In this Optimum Perspectives celebratory episode for International Day of Women & Girls in Science, hear from five influential women on how they broke down gender barriers to succeed in the life science industry.
See today’s investors signing the most cheques in European healthtech in 2023, according to Dealroom data
BII is a non-profit accelerator/incubator, backed by a €470m donation from the Novo Nordisk Foundation. It backs pre-seed and pre-investment startups, including disease diagnostics startup Rapidemic and cancer treatment platform Metsystem.
See today’s BioWorld MedTech
Metsystem receives injection of funds to validate cancer metastasis prognosis platform
MEDWATCH 22.3.2023
Entrepreneurs create prognosis service for hospitals: Will identify patients at high risk of metastases.
Newly founded Metsystem aims to make its prognosis service available in 2025 initially to hospitals in Denmark, but later abroad and to pharmaceutical companies as a test of their cancer treatment in the preclinical stage.
